<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140004137A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140004137</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13992526</doc-number><date>20111209</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><priority-claims><priority-claim sequence="01" kind="regional"><country>EP</country><doc-number>PCT/EP2010/069246</doc-number><date>20101209</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>7</main-group><subgroup>06</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>7</main-group><subgroup>06</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>4241851</main-classification><further-classification>530328</further-classification><further-classification>530333</further-classification></classification-national><invention-title id="d0e61">IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>Ovaa</last-name><first-name>Huib</first-name><address><city>Amsterdam</city><country>NL</country></address></addressbook><residence><country>NL</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only"><addressbook><last-name>Rodenko</last-name><first-name>Boris</first-name><address><city>Amsterdam</city><country>NL</country></address></addressbook><residence><country>NL</country></residence></us-applicant><us-applicant sequence="02" app-type="applicant" designation="us-only"><addressbook><last-name>Hoppes</last-name><first-name>Rieuwert</first-name><address><city>Amsterdam</city><country>NL</country></address></addressbook><residence><country>NL</country></residence></us-applicant><us-applicant sequence="03" app-type="applicant" designation="us-only"><addressbook><last-name>Amore</last-name><first-name>Alessia</first-name><address><city>Amsterdam</city><country>NL</country></address></addressbook><residence><country>NL</country></residence></us-applicant><us-applicant sequence="04" app-type="applicant" designation="us-only"><addressbook><last-name>Schumacher</last-name><first-name>Antonius Nicolaas Maria</first-name><address><city>Amsterdam</city><country>NL</country></address></addressbook><residence><country>NL</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Ovaa</last-name><first-name>Huib</first-name><address><city>Amsterdam</city><country>NL</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Rodenko</last-name><first-name>Boris</first-name><address><city>Amsterdam</city><country>NL</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Hoppes</last-name><first-name>Rieuwert</first-name><address><city>Amsterdam</city><country>NL</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Amore</last-name><first-name>Alessia</first-name><address><city>Amsterdam</city><country>NL</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Schumacher</last-name><first-name>Antonius Nicolaas Maria</first-name><address><city>Amsterdam</city><country>NL</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>STICHTING SANQUIN BLOEDVOORZIENING</orgname><role>03</role><address><city>Amsterdam</city><country>NL</country></address></addressbook></assignee><assignee><addressbook><orgname>STICHTING HET NEDERLANDS KANKER INSTITUUT</orgname><role>03</role><address><city>Amsterdam</city><country>NL</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/EP2011/072377</doc-number><kind>00</kind><date>20111209</date></document-id><us-371c124-date><date>20130607</date></us-371c124-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Immune-restricted peptides, especially HLA-A2 restricted peptides. Specifically, immune-restricted peptides according to the formula:</p><p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="3.39mm" wi="48.60mm" file="US20140004137A1-20140102-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0003" num="0000">wherein:<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0000">P<sub>1 </sub>is selected from the group consisting of am-phg, PHG, 3-PYRA, 3-THI, SOME, CSCF3 and CSME;</li>        <li id="ul0002-0002" num="0000">P<sub>2</sub>, P<sub>3</sub>, P<sub>4</sub>, P<sub>C-2</sub>, P<sub>C-1</sub>, and P<sub>C </sub>are each independently a naturally, or non-naturally, occurring amino acid, wherein</li>        <li id="ul0002-0003" num="0000">P<sub>2 </sub>and P<sub>3 </sub>each comprise a hydrophobic linear or branched substitution, wherein</li>        <li id="ul0002-0004" num="0000">P<sub>2 </sub>can further be a fluorinated substitution,</li>        <li id="ul0002-0005" num="0000">P<sub>4 </sub>comprises a methylated alpha nitrogen atom;</li>        <li id="ul0002-0006" num="0000">P<sub>C-2 </sub>comprises a fluorinated aromatic substitution;</li>        <li id="ul0002-0007" num="0000">P<sub>C </sub>comprises unsaturated or saturated side chains and/or carboxyl isosteres, or a saturated linear carbon chain containing 2 to 4 carbon atoms with or without an oxygen or sulphur atom within the chain and/or a carboxyl isostere;</li>        <li id="ul0002-0008" num="0000">P<sub>m </sub>is a naturally occurring amino acid; and</li>        <li id="ul0002-0009" num="0000">n is an integer of 1-9.</li>    </ul>    </li></ul></p></abstract></us-patent-application>